BioTelemetry (NASDAQ: BEAT) and BG Medicine (OTCMKTS:BGMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.
Insider and Institutional Ownership
76.4% of BioTelemetry shares are owned by institutional investors. 9.6% of BioTelemetry shares are owned by insiders. Comparatively, 6.5% of BG Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of current ratings for BioTelemetry and BG Medicine, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioTelemetry presently has a consensus target price of $43.50, indicating a potential upside of 69.92%. Given BioTelemetry’s higher possible upside, equities analysts plainly believe BioTelemetry is more favorable than BG Medicine.
This table compares BioTelemetry and BG Medicine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
BioTelemetry has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, BG Medicine has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500.
Earnings & Valuation
This table compares BioTelemetry and BG Medicine’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|BioTelemetry||$208.33 million||3.98||$53.43 million||$1.31||19.54|
|BG Medicine||$1.57 million||0.34||-$5.30 million||N/A||N/A|
BioTelemetry has higher revenue and earnings than BG Medicine.
BioTelemetry beats BG Medicine on 10 of the 11 factors compared between the two stocks.
BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company’s research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).
About BG Medicine
BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners’ automated platforms. The Company’s CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.